Guy de Bruyn1. 1. Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. debruyng@phru.co.za
Abstract
PURPOSE OF REVIEW: This review summarizes recent developments related to cofactors that may influence response to vaccination. RECENT FINDINGS: The unexpected increased HIV acquisition among vaccinees in the Step trial with prior exposure to adenovirus type 5 (Ad5) led to several studies trying to understand whether an underlying biological risk factor may have been responsible for this observation. Demographic factors and genetic background of the human populations in HIV vaccine trials remain a source of potential variation in responses observed in vaccine trials, yet empirical data remain limited on the impact of those factors. Coinfections, particularly those that may modulate the immune response, are a further concern for HIV vaccine trialists, with recent data providing further insight into effects of coinfections on innate and adaptive immunity and vaccine responses. SUMMARY: Individuals and human populations display variation in response to vaccination. Key explanatory variables for this variation include host factors, such as host genetics, and environmental factors, such as prior exposure to the vaccine vector, coinfection with other pathogens, and demographic factors. This review will outline some of the recent developments investigating the role of various cofactors on vaccine responses, with a particular emphasis on studies of HIV vaccines.
PURPOSE OF REVIEW: This review summarizes recent developments related to cofactors that may influence response to vaccination. RECENT FINDINGS: The unexpected increased HIV acquisition among vaccinees in the Step trial with prior exposure to adenovirus type 5 (Ad5) led to several studies trying to understand whether an underlying biological risk factor may have been responsible for this observation. Demographic factors and genetic background of the human populations in HIV vaccine trials remain a source of potential variation in responses observed in vaccine trials, yet empirical data remain limited on the impact of those factors. Coinfections, particularly those that may modulate the immune response, are a further concern for HIV vaccine trialists, with recent data providing further insight into effects of coinfections on innate and adaptive immunity and vaccine responses. SUMMARY: Individuals and human populations display variation in response to vaccination. Key explanatory variables for this variation include host factors, such as host genetics, and environmental factors, such as prior exposure to the vaccine vector, coinfection with other pathogens, and demographic factors. This review will outline some of the recent developments investigating the role of various cofactors on vaccine responses, with a particular emphasis on studies of HIV vaccines.
Authors: Diane M Roberts; Anjali Nanda; Menzo J E Havenga; Peter Abbink; Diana M Lynch; Bonnie A Ewald; Jinyan Liu; Anna R Thorner; Patricia E Swanson; Darci A Gorgone; Michelle A Lifton; Angelique A C Lemckert; Lennart Holterman; Bing Chen; Athmanundh Dilraj; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Dan H Barouch Journal: Nature Date: 2006-04-16 Impact factor: 49.962
Authors: Helen S Goodridge; Fraser A Marshall; Kathryn J Else; Katrina M Houston; Caitlin Egan; Lamyaa Al-Riyami; Foo-Yew Liew; William Harnett; Margaret M Harnett Journal: J Immunol Date: 2005-01-01 Impact factor: 5.422
Authors: Charles S Morrison; Barbra A Richardson; Francis Mmiro; Tsungai Chipato; David D Celentano; Joanne Luoto; Roy Mugerwa; Nancy Padian; Sungwal Rugpao; Joelle M Brown; Peter Cornelisse; Robert A Salata Journal: AIDS Date: 2007-01-02 Impact factor: 4.177
Authors: David C Montefiori; Barbara Metch; M Juliana McElrath; Steve Self; Kent J Weinhold; Lawrence Corey Journal: J Infect Dis Date: 2004-10-28 Impact factor: 5.226
Authors: B D Livingston; J Alexander; C Crimi; C Oseroff; E Celis; K Daly; L G Guidotti; F V Chisari; J Fikes; R W Chesnut; A Sette Journal: J Immunol Date: 1999-03-01 Impact factor: 5.422
Authors: C L Karp; M Wysocka; L M Wahl; J M Ahearn; P J Cuomo; B Sherry; G Trinchieri; D E Griffin Journal: Science Date: 1996-07-12 Impact factor: 47.728
Authors: Esther E Freeman; Helen A Weiss; Judith R Glynn; Pamela L Cross; James A Whitworth; Richard J Hayes Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Kennedy N Otwombe; Kathleen J Sikkema; Janan Dietrich; Guy de Bruyn; Martin van der Watt; Glenda E Gray Journal: J Acquir Immune Defic Syndr Date: 2011-10-01 Impact factor: 3.731
Authors: Jenna Anderson; Thorunn A Olafsdottir; Sven Kratochvil; Paul F McKay; Malin Östensson; Josefine Persson; Robin J Shattock; Ali M Harandi Journal: Front Immunol Date: 2018-02-26 Impact factor: 7.561
Authors: Ido Somekh; Wasiur R KhudaBukhsh; Elisabeth Dowling Root; Lital Keinan Boker; Grzegorz Rempala; Eric A F Simões; Eli Somekh Journal: Open Forum Infect Dis Date: 2022-02-18 Impact factor: 4.423
Authors: Sandra G Okala; Momodou K Darboe; Fatou Sosseh; Bakary Sonko; Tisbeh Faye-Joof; Andrew M Prentice; Sophie E Moore Journal: PLoS Med Date: 2019-08-06 Impact factor: 11.069
Authors: Sandra G Okala; Momodou K Darboe; Fatou Sosseh; Bakary Sonko; Tisbeh Faye-Joof; Andrew M Prentice; Sophie E Moore Journal: BMC Public Health Date: 2021-07-22 Impact factor: 3.295